Reports Q1 revenue $106.68M, consensus $107.08M. “We are proud to report another quarter of strong commercial performance, with KIMMTRAK generating $107 million in net revenues in Q1 2026,” said Bahija Jallal, CEO of Immunocore (IMCR). “The five-year overall survival (OS) data from our Phase 3 trial presented at AACR is a landmark moment. It is the longest OS follow-up ever reported in a randomized trial in metastatic uveal melanoma and underscores the long-term benefit KIMMTRAK delivers to patients. In parallel, we are executing with discipline across our pipeline.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Needham’s Gil Blum Reiterates Buy on Strong Execution, Robust Pipeline and Solid Cash Runway, Keeps $75 Price Target Unchanged
- Immunocore (IMCR): KIMMTRAK’s Durable Survival Benefit in Metastatic Uveal Melanoma Underpins Sustainable Growth and $100 Buy Rating
- Immunocore announces five-year overall survival data for Kimmtrak
- Immunocore: KIMMTRAK’s Durable Leadership in Metastatic Uveal Melanoma Underpins Buy Rating and $100 Target
- Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating